Long-term survival after immunotherapy and targeted therapy without chemotherapy in an elderly patient with HER2-positive gastroesophageal junction cancer: A case report

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):1–5. doi:10.3322/caac.21660.
   Web of Science ®Google Scholar
• Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–84. doi:10.1007/s10120-014-0402-y.
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. doi:10.1016/S0140-6736(10)61121-X.
   PubMed Web of Science ®Google Scholar
• FDA Approves Merck’s KEYTRUDA® (pembrolizumab). Combined with trastuzumab and chemotherapy as first-line treatment in locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
   Google Scholar
• Dai C, Lin F, Geng R, Ge X, Tang W, Chang J, Wu Z, Liu X, Lin Y, Zhang Z, et al. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget. 2016;7(9):10332–44. doi:10.18632/oncotarget.7243.
   PubMedGoogle Scholar
• Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, Tang L, Xin Y, Jin J, Zhang Y-J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (London, England). 2019;39(1):10. doi:10.1186/s40880-019-0349-9.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQM, Juco J, Lunceford J, Saraf S, Perini RF, O’Donnell PH. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212–20. doi:10.1016/S1470-2045(17)30007-4.
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmoller P, Gutjahr T, Kaufmann M, Henkel T, Ruschoff J. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol. 2008;61(1):89–94. doi:10.1136/jcp.2006.043562.
   PubMed Web of Science ®Google Scholar
• FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express PD-L1 (CPS greater than or equal to 1). 2017.
   Google Scholar
• Wang S, Wang X, Zhou X, Lyerly HK, Morse MA, Ren J. DC-CIK as a widely applicable cancer immunotherapy. Expert Opin Biol Ther. 2020;20(6):601–07. doi:10.1080/14712598.2020.1728250.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31. doi:10.1016/S1470-2045(20)30169-8.
   PubMed Web of Science ®Google Scholar
• Rha SY, Lee C-K, Kim HS, Kang B, Jung M, Bae WK, Koo, D-H, Shin, S-J, Jeung, H-C, Zang, DY , et al. Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC). J Clin Oncol. 2022;38(15_suppl):3081–. doi:10.1200/JCO.2020.38.15_suppl.3081.
   Google Scholar
• Chung HC, Bang Y-J, S Fuchs C, S-K Qin, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol (London, England). 2021;17(5):491–501. doi:10.2217/fon-2020-0737.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Kang Y-K, Park H, Uronis HE, Lee K-W, Mch N, Enzinger PC, Park SH, Gold PJ, Lacy J, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. Lancet Oncol. 2020;21(8):1066–76. doi:10.1016/S1470-2045(20)30326-0.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 2013;11(1):83. doi:10.1186/1479-5876-11-83.
   PubMedGoogle Scholar
• Han Y, Mu D, Liu T, Zhang H, Zhang J, Li S, Wang R, Du W, Hui Z, Zhang X, et al. Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: a preliminary study. Thoracic Cancer. 2020;12(2):145–52. doi:10.1111/1759-7714.13731.
   PubMed Web of Science ®Google Scholar
• Dehno MN, Li Y, Weiher H, Schmidt-Wolf IGH. Increase in efficacy of checkpoint inhibition by cytokine-induced-killer cells as a combination immunotherapy for renal cancer. Int J Mol Sci. 2020;21(9):21. doi:10.3390/ijms21093078.
   Web of Science ®Google Scholar
• Cappuzzello E, Tosi A, Zanovello P, Sommaggio R, Rosato A. Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology. 2016;5(8):e1199311. doi:10.1080/2162402X.2016.1199311.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges J-P, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013.
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–80. doi:10.1001/jamaoncol.2020.3370.
   PubMed Web of Science ®Google Scholar